Key Events This Week
1 June: Q4 FY26 results reveal losses and collapsing operating margins despite revenue growth
2 June: Intraday high surge of 8.26% and downgrade to Strong Sell by MarketsMOJO
3 June: Technical upgrade to Sell amid improving momentum despite weak fundamentals
4 June: Strong intraday rally of 8.78%, hitting Rs.476.25
5 June: Week closes at Rs.541.10, up 3.96% on the day
Panacea Biotec Ltd’s Volatile Week: 9.98% Surge and 9.99% Plunge Highlight Market Dynamics
2026-06-13 13:01:07
Key Events This Week
8 Jun: Mojo Grade upgraded to Sell amid technical improvements
9 Jun: New 52-week and all-time highs at Rs.619.05 and Rs.608.8
10 Jun: Sharp plunge to lower circuit amid heavy selling
12 Jun: Week closes at Rs.537.30, down 0.70%

Panacea Biotec Ltd Locks at Lower Circuit With 9.87% Loss — Sellers Queue, No Buyers in Sight
2026-06-10 15:00:08At Rs 547.75, sellers were still queuing — but there were no buyers willing to take the other side. Panacea Biotec Ltd locked at its lower circuit of 9.87% on 10 Jun 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.
Read full news article
Panacea Biotec Ltd Hits Intraday Low Amid Price Pressure on 10 Jun 2026
2026-06-10 09:31:56Panacea Biotec Ltd experienced a notable decline today, touching an intraday low of Rs 573.85, reflecting a sharp price correction amid heightened volatility and broader market dynamics. The stock underperformed its sector and reversed a six-day gaining streak, signalling immediate pressures on its intraday performance.
Read full news article
Panacea Biotec Ltd Sees Strong Technical Momentum Amid Market Rally
2026-06-10 08:03:28Panacea Biotec Ltd has demonstrated a remarkable shift in price momentum, transitioning from a sideways trend to a bullish trajectory, supported by a confluence of positive technical indicators. The stock’s recent surge, marked by a 9.98% gain on 10 Jun 2026, reflects renewed investor confidence amid broader market challenges, with the company outperforming the Sensex significantly across multiple time horizons.
Read full news article
Panacea Biotec Ltd Forms Golden Cross Amid Mixed Technical Signals and Strong Recent Rally
2026-06-09 18:00:56The 50-day moving average for Panacea Biotec Ltd has crossed above the 200-day moving average, creating a golden cross on 09 Jun 2026. While this technical event often signals a shift towards bullish momentum, the broader technical and fundamental context presents a more nuanced picture that warrants careful analysis.
Read full news article
Panacea Biotec Ltd Surges on High-Value Trading Amid Institutional Interest
2026-06-09 13:00:16Panacea Biotec Ltd witnessed a remarkable surge in trading activity on 9 June 2026, emerging as one of the most actively traded stocks by value in the Pharmaceuticals & Biotechnology sector. The stock soared to a new 52-week high, buoyed by strong institutional interest and robust order flow, delivering a stellar 14.55% gain on the day and outperforming its sector by over 12.6%.
Read full news article
Broad-Based Technical Strength Lifts Panacea Biotec Ltd to 52-Week High of Rs 619.05
2026-06-09 09:40:11With a decisive surge to Rs 619.05 on 09 Jun 2026, Panacea Biotec Ltd has reached a fresh 52-week high, marking a remarkable rally from its low of Rs 293.10. This milestone reflects a sustained momentum driven by a confluence of technical indicators aligning favourably across multiple timeframes.
Read full news article
Panacea Biotec Ltd Hits All-Time High of Rs 608.8 as Momentum Builds Across Timeframes
2026-06-09 09:31:40Extending a remarkable six-day winning streak, Panacea Biotec Ltd surged to a fresh all-time high of Rs 608.8 on 09 Jun 2026, outperforming its sector and the broader market by a wide margin.
Read full news articleAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
08-Jun-2026 | Source : BSEPanacea Biotec is pleased to inform the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll in sub-Saharan Africa (sSA) and to facilitate its broader global use. A copy of the Press Release is attached herewith.
Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011
05-Jun-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Jain HUF
Details Of Shares Dematerialized During May 2026 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018
05-Jun-2026 | Source : BSEPlease find attached details of shares dematerialised during May 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018
Corporate Actions
No Upcoming Board Meetings
Panacea Biotec Ltd has declared 75% dividend, ex-date: 19 Sep 11
No Splits history available
No Bonus history available
No Rights history available






